Journals

  1. Lorentzian A, Biegel JA, Ostrow DG, Rolf N, Liu CC, Rassekh SR, Deyell RJ, Triche T, Schultz KR, Rozmus J, Reid GSD, Lim CJ, Lange PF, Maxwell CA. Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies. JNCI Cancer Spectr. 2018 Oct;2(4):pky079. doi: 10.1093/jncics/pky079. Epub 2019 Jan 25. PMID: 30976750; PMCID: PMC6447067.
     
  2. Uzozie AC, Ergin EK, Rolf N, Tsui J, Lorentzian A, Weng SSH, Nierves L, Smith TG, Lim CJ, Maxwell CA, Reid GSD, Lange PF. PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways. J Exp Clin Cancer Res. 2021 Mar 15; 40(1):96. doi: 10.1186/s13046-021-01835-8. PMID: 33722259; PMCID: PMC7958471.
     
  3. *Rolf N, Liu LYT, Tsang A, Lange PF, Lim CJ, Maxwell CA, Vercauteren SM, Reid GSD. A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts. Cytometry A. 2022 Jan;101(1):57-71. doi: 10.1002/cyto.a.24473. Epub 2021 Jun 25. PMID: 34128309; PMCID: PMC9292200.

    *Featured as one of two “must-read” articles in the monthly roundup of the European Journal of Immunology. Dissecting phenotypic subpopulation complexity in childhood leukemia for PDX-based precision medicine approaches. Eur. J. Immunol. (2021) 51(9):2114, DOI: 10.1002/eji.202170094.
     
  4. Barnabas GD, Goebeler V, Tsui J, Bush JW, Lange PF. ASAP─Automated Sonication-Free Acid-Assisted Proteomes─from Cells and FFPE Tissues. Anal Chem. 2023 Feb 14;95(6):3291-3299. doi: 10.1021/acs.analchem.2c04264. Epub 2023 Feb 1. PMID: 36724070; PMCID: PMC9933881.
     
  5. Lorentzian AC, Rever J, Ergin EK, Guo M, Akella NM, Rolf N, Lim CJ, Reid GSD, Maxwell CA, Lange PF. Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia. Nat Commun. 2023 Nov 21;14(1):7161. doi: 10.1038/s41467-023-42701-9. PMID: 37989729; PMCID: PMC10663560.

Meeting Abstracts

  1. Barnabas GD, Bhat TA, Goebeler V, Maxwell CM, Reid GS, Senger D, Parker S, Bush J, Strahlendorf C, Deyell R, Lim CJ, Lange PF, and on behalf of the PROFYLE program. Prioritizing treatment targets for a rare pediatric malignancy using proteomics and personalized xenograft models within an actionable timeframe. 9th TFRI Scientific Meeting, Vancouver. Nov, 2022 (Poster)
     
  2. Bhat TA, Barnabas GD, Goebeler V, Leclair P, Maxwell CM, Deyell R, Strahlendorf C, Bush J, Reid GS, Lange PF, Lim CJ, on behalf of the PROFYLE program. Evaluating Targeted Drug Therapies for Pediatric Tumours Using the Chick Chorioallantoic Membrane (CAM) Xenograft Model. 9th TFRI Scientific Meeting, Vancouver. Nov, 2022 (Poster & Rapid-Fire Talk)
     
  3. Barnabas GD, Bhat TA, Goebeler V, Maxwell CM, Reid GS, Senger D, Parker S, Bush J, Strahlendorf C, Deyell R, Lim CJ, Lange PF, and on behalf of the PROFYLE program. Prioritizing treatment targets for a rare pediatric malignancy using proteomics and personalized xenograft models within an actionable timeframe. Zero Childhood Cancer (ZERO) National Symposium. Oct, 2022 (Poster & Rapid-Fire Talk)
     
  4. Rolf N, Liu LYT, Tsang A, Vercauteren SM, Reid GSD. Stability of leukemia immunophenotypes through disease progression. BCCHR Childhood Diseases Theme Symposium. Oct, 2022 (Poster)
     
  5. Lorentzian A, Guo M, Ergin EK, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Proteogenomic analysis identifies the persistence of targetable genomes and proteomes through disease evolution in pediatric acute lymphoblastic leukemia. International Society of Pediatric Oncology (SIOP) Conference Barcelona, Spain. Sept, 2022 (Poster & Discussion Panel)
     
  6. Lorentzian A, Guo M, Ergin EK, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of targetable lesions and proteomes through disease evolution in pediatric acute lymphoblastic leukemia. Canadian National Proteomics Network (CNPN) Conference Montreal, QC. May, 2022 (Oral Presentation)
     
  7. Leclair P, Lorentzian A, Rolf N, Goebeler V, Lange P, Maxwell C, Reid G, and Lim CJ. A Pre-Clinical Platform to Assess Efficacy for Precision Molecular Targeted Therapies in Pediatric Acute Lymphoblastic Leukemia. SIOP 2021 Virt Congress. Oct, 2021 (Poster)
     
  8. Rolf N, Liu LYT, Lorentzian A, Leclair P, Goebeler V, Lange PF, Lim CJ, Maxwell CA, Vercauteren SM, Reid GSD. Longitudinal assessment of phenotypic heterogeneity and subpopulation trajectories in B-ALL disease progression samples, 53rd Congress of the International Society of Pediatric Oncology (SIOP, Virtual). Pediatric Blood and Cancer (2021), 68: S166, #1443, Oct 2021 (Poster).
     
  9. Lorentzian A, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of proteomes, targetable lesions, and therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia. International Society of Pediatric Oncology (SIOP) Conference (Virtual) Sept, 2021 (Poster).
     
  10. Lorentzian A, Rolf N, Leclair P, Akella N, Gregor S.D. Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of targetable lesions, proteome state, and predicted drug sensitivity through disease progression in pediatric acute lymphoblastic leukemia. Canadian National Proteomics Network (CNPN) Conference (Virtual) May, 2021. (Oral Presentation).
     
  11. Rolf N, Tsang A, Liu LYT, Lorentzian A, Leclair P, Patterson A, Lange PF, Maxwell CA, Lim CJ, Klein-Geltink R, Vercauteren SM, Reid GSD. MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initating Potential, 63rd Annual Meeting of the American Society of Hematology (ASH, Virtual). Blood 136, S1: 12-13. Dec, 2020 (Poster). 
     
  12. Rolf N, Liu LYT, Tsang A, Vercauteren SM, Reid GSD. A cross-standardized analytical platform to permit comparison of immunophenotypic subpopulations between acute lymphoblastic leukemia patients and their patient-derived xenografts, Annual Meeting of the International Clinical Cytometry Society (ICCS, Virtual). Sept, 2020 (Poster; *1 out 5 Panelists selected for Virtual Poster Walk)
     
  13. Lorentzian A, Rolf N, Reid GSD, Lim CJ, Lange PF and Maxwell CA. Accounting for the Unique Molecular Landscape of Pediatric Malignancies Improves Target-Agent Pair Identification for Pediatric Precision Oncology. American Society of Hematology (ASH), San Diego, USA. Dec, 2018. (Poster)
     

  14. Uzozie A, Ergin E, Lorentzian A, Rolf N, Lim CJ, Reid G, Maxwell CA, and Lange PF. Patient-derived xenograft models recapitulate the proteome and functional capacity of primary pediatric acute lymphoblastic leukemia but divert in select pathways. International Society of Pediatric Oncology (SIOP) Conference (Virtual) Sept, 2021 (Poster).
     

  15. Uzozie A, Tsui J, Maxwell CA, Lim CJ, Reid G, and Lange PF. Integrated proteome, phospho-proteome and N terminome characterization of pediatric patient and matched engrafted leukemia. Canadian National Proteomics Network (CNPN) Conference, Montreal, QC. May, 2019 (Oral Presentation).